Piper Sandler analyst David Amsellem raised the firm’s price target on Avadel Pharmaceuticals to $18 from $13 and keeps an Overweight rating on the shares post the Q2 report. The analyst cites strong early color on Lumryz commercial dynamics for the target raise.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AVDL:
- Avadel Pharmaceuticals reports Q2 EPS (83c), consensus (38c)
- Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Is AVDL a Buy, Before Earnings?
- Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Needham healthcare/neuroscience analyst holds analyst/industry conference call